Third Harmonic Bio to Participate in Upcoming Investor Conferences
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. CEO Natalie Holles will engage in fireside chats at the following events:
- Morgan Stanley 22nd Healthcare Conference on September 4, 2024, at 9:15 a.m. ET
- Stifel 2024 Virtual Immunology and Inflammation Summit on September 18, 2024, at 9:00 a.m. ET
The company, which focuses on developing innovative treatments for dermal, respiratory, and gastrointestinal inflammatory diseases, will provide live audio webcasts of these presentations. These webcasts will be accessible through the Investors & Media section of Third Harmonic Bio's website, with archived replays available for 90 days after each event.
Third Harmonic Bio (Nasdaq: THRD), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione a due prossimi conferenze per investitori. L'amministratore delegato Natalie Holles parteciperà a conversazioni informali nei seguenti eventi:
- 22ª Conferenza Sanitaria Morgan Stanley il 4 settembre 2024, alle 9:15 ET
- Summit Virtuale di Immunologia e Infiammazione Stifel 2024 il 18 settembre 2024, alle 9:00 ET
L'azienda, che si concentra sullo sviluppo di trattamenti innovativi per malattie infiammatorie dermatologiche, respiratorie e gastrointestinali, fornirà webcast audio dal vivo di queste presentazioni. I webcast saranno accessibili attraverso la sezione Investitori & Media del sito web di Third Harmonic Bio, con repliche archiviate disponibili per 90 giorni dopo ciascun evento.
Third Harmonic Bio (Nasdaq: THRD), una empresa biofarmacéutica en etapa clínica, ha anunciado su participación en dos próximas conferencias para inversionistas. La CEO Natalie Holles participará en charlas informales en los siguientes eventos:
- 22ª Conferencia de Salud de Morgan Stanley el 4 de septiembre de 2024, a las 9:15 a.m. ET
- Cumbre Virtual de Inmunología e Inflamación de Stifel 2024 el 18 de septiembre de 2024, a las 9:00 a.m. ET
La empresa, que se centra en desarrollar tratamientos innovadores para enfermedades inflamatorias dérmicas, respiratorias y gastrointestinales, proporcionará transmisiones web de audio en vivo de estas presentaciones. Estas transmisiones estarán disponibles a través de la sección de Inversores y Medios en el sitio web de Third Harmonic Bio, con repeticiones archivadas disponibles durante 90 días después de cada evento.
제3 하모닉 바이오 (Nasdaq: THRD)는 임상 단계의 바이오 제약 회사로, 두 개의 투자자 회의에 참여한다고 발표했습니다. CEO Natalie Holles는 다음 행사에서 토크 세션에 참석할 예정입니다:
- 모건 스탠리 제22회 헬스케어 컨퍼런스 2024년 9월 4일 오전 9시 15분 ET
- 스티펠 2024년 가상 면역학 및 염증 정상 회담 2024년 9월 18일 오전 9시 ET
이 회사는 피부, 호흡기 및 위장 염증성 질환을 위한 혁신적인 치료법 개발에 중점을 두고 있으며, 이 프레젠테이션에 대한 라이브 오디오 웹캐스트를 제공할 것입니다. 이 웹캐스트는 제3 하모닉 바이오 웹사이트의 투자자 및 미디어 섹션을 통해 접근할 수 있으며, 각 사건 이후 90일 동안 아카이브된 재생이 가능합니다.
Third Harmonic Bio (Nasdaq: THRD), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à deux prochaines conférences pour investisseurs. La PDG Natalie Holles participera à des discussions informelles lors des événements suivants :
- 22ème Conférence sur la santé de Morgan Stanley le 4 septembre 2024 à 9h15 ET
- Sommet virtuel sur l'immunologie et l'inflammation de Stifel 2024 le 18 septembre 2024 à 9h00 ET
L'entreprise, qui se concentre sur le développement de traitements innovants pour des maladies inflammatoires dermatologiques, respiratoires et gastrointestinales, proposera des webcasts audio en direct de ces présentations. Ces webcasts seront accessibles par le biais de la section Investisseurs & Médias du site Web de Third Harmonic Bio, avec des rediffusions archivées disponibles pendant 90 jours après chaque événement.
Third Harmonic Bio (Nasdaq: THRD), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. CEO Natalie Holles wird bei den folgenden Veranstaltungen an Gesprächsrunden teilnehmen:
- 22. Morgan Stanley Gesundheitskonferenz am 4. September 2024 um 9:15 Uhr ET
- Stifel 2024 Virtueller Immunologie- und Entzündungsgipfel am 18. September 2024 um 9:00 Uhr ET
Das Unternehmen, das sich auf die Entwicklung innovativer Behandlungen für dermato-, respiratorische und gastrointestinal entzündliche Erkrankungen konzentriert, wird Live-Audio-Webcasts dieser Präsentationen bereitstellen. Diese Webcasts werden über den Bereich Investoren & Medien auf der Website von Third Harmonic Bio zugänglich sein, mit archivierten Wiederholungen, die 90 Tage nach jeder Veranstaltung verfügbar sind.
- None.
- None.
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the following upcoming conferences:
- Morgan Stanley 22nd Healthcare Conference on Wednesday, September 4, 2024, at 9:15 a.m. ET
- Stifel 2024 Virtual Immunology and Inflammation Summit on Wednesday, September 18, 2024, at 9:00 a.m. ET
A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event.
About Third Harmonic Bio, Inc.
Third Harmonic Bio is a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate, THB335, is a titratable, oral, small molecule inhibitor that is currently in a Phase 1 clinical trial. For more information, please visit the Third Harmonic Bio website: www.thirdharmonicbio.com.
Investor and Media Contact:
Lori Murray
lori.murray@thirdharmonicbio.com
FAQ
When is Third Harmonic Bio (THRD) participating in the Morgan Stanley Healthcare Conference?
What is the date for Third Harmonic Bio's (THRD) presentation at the Stifel Virtual Immunology and Inflammation Summit?
How long will the webcasts of Third Harmonic Bio's (THRD) investor conference presentations be available?
What therapeutic areas does Third Harmonic Bio (THRD) focus on?
